Microfluidizer Á¾ÇÕÄ«´Ù·Î±×


Phone
  ´ëÇ¥ÀüÈ­ 1577-7956  
  º»     »ç 031-457-9187  
  ´ë     Àü 042-932-1265

Web Site Visitors
  Today 534    
  Yesterday 637    
  Since 2006 1,757,456    


| ¸®½ºÆ®µ¹¾Æ°¡±â |
 
¡Ø ÂüÁ¶³í¹® : An Alphavirus-derived replicon RNA vaccine
                Jesse H. Erasmus, et al., SCIENCE TRANSLATIONAL MEDICINE, 2020


2020³â ¹Ì±¹ HDT Bio (Host Directed Therapeutics Biotechnology) »ç´Â °­·ÂÇÑ RNA Delivery Ç÷§ÆûÀÎ LION¢â (Lipid Iron Oxide Nanoparticles) RNA Delivery System À» °³¹ßÇÏ¿´½À´Ï´Ù.


LION¢â RNA Delivery System Àº ´ÙÀ½ ³»¿ëÀ¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù.
Squalene : Vaccine Adjuvant ±â´ÉÀ» Çϸç LION¢â ÀÇ °ñ°ÝÀ» Çü¼ºÇÏ´Â ¿ªÇÒ
SPIO : Super paramagnetic Iron Oxide, Fe3O4, ¾çÀ̿»êȭö : ¾çÀÌ¿ÂÀ» ¶ç°í ÀÖ¾î RNA ¿Í °áÇÕÇÏ´Â ±â´É
DOTAP : the cationic lipid 1,2-dioleoyl-3-trimethylammonium propane : RNA ¿Í °áÇÕÇÏ¿© RNA-combined LION¢â À» ¸Å¿ì stable »óÅ·ΠÀ¯Áö½ÃÄÑ ÁÖ´Â ÇÙ½ÉÀûÀÎ ±â´É
SPAN 60 : °è¸éÈ°¼ºÁ¦
Tween 80 : °è¸éÈ°¼ºÁ¦

LION¢â system À» RNA ¿Í mixing Çϸé RNA °¡ LION¢â ¿¡ °­ÇÏ°Ô °áÇÕÇÏ¿© RNA-combined LION ÀÌ µÈ´Ù.



RNA-combined LION¢â ÀÇ RNA °¡ ¾î´À Á¤µµ ¾ÈÁ¤ÇÏ°Ô Á¸ÀçÇÏ´ÂÁö È®ÀÎÇϱâ À§ÇØ RNAse ó¸®ÇÏ¿© Àü±â¿µµ¿À¸·Î È®ÀÎÇÑ °á°ú LION¢â ¿¡ combined µÈ RNA ´Â ¸Å¿ì ¾ÈÁ¤ÇÑ »óŸ¦ À¯ÁöÇÏ´Â °ÍÀ» ¾Ë ¼ö ÀÖ¾ú´Ù.



¶ÇÇÑ LION¢â ¿¡ combine µÈ RNA ´Â ¿Âµµº¯È­¿¡µµ ¸Å¿ì ¾ÈÁ¤ÇÑ »óŸ¦ À¯ÁöÇÏ°í ÀÖ´Â °ÍÀ» È®ÀÎÇÒ ¼ö ÀÖ¾ú´Ù.



LION¢â formulation

LION¢â formulation that SPIO nanoparticles within a hydrophobic squalene core to enhance formulation stability.

- 37.5 mg/ml squalene
- 30 mg/ml DOTAP chloride
- 37 mg/ml Span¢ç 60
- 37 mg/ml Tween¢ç 80

LION¢â formulation °úÁ¤

1 combine the iron oxide nanoparticles with the oil phase (Squalene, Span 60, and DOTAP)
2 sonicate for 30 minutes in a 65¡ÆC water bath
3 Separately, the aqueous phase, containing Tween 80 in water, was prepared with continuous stirring until all components were dissolved.
4 The oil and aqueous phases were then mixed and emulsified using mixer
5 the crude colloid was subsequently processed by passaging through a microfluidizer at 20,000 psi with a LM10 microfluidizer equipped with a H10Z-100 ¥ìm ceramic interaction chamber (Microfluidics) until the z-average hydrodynamic diameter - reached 50 ¡¾5 nm with a 0.2 polydispersity index.
6 The microfluidized LION¢â was terminally filtered with a 200 nm pore-size polyethersulfone (PES) filter and stored at 2-8¡ÆC
7 Replicon RNA was complexed with LION¢â formulations and placed on ice for 30 min

LION¢â RNA Delivery Platform Ư¡

- ¸Å¿ì ¸¹Àº ¾çÀÇ target ´Ü¹éÁúÀ» »ý¼ºÇÏ¿© ºü¸¥ ¸é¿ª ¶Ç´Â Ä¡·á ÀÛ¿ëÀ» ±â´ë (~50¹è)
- ÀÎü³»¿¡¼­ ¸Å¿ì ¾ÈÁ¤ÇÏ´Ù,
- ¸é¿ªº¸°­Á¦ (vaccine adjuvant) °¡ Æ÷ÇԵǾî ÀÖ´Ù.
- »ó¿Â º¸°üÀÌ °¡´É
- °¡°ÝÀÌ Àú·Å
- Á¦Á¶°¡ ¸Å¿ìÆí¸®ÇÏ´Ù


LION¢â RNA Delivery System À» ÀÌ¿ëÇÏ¿© COVID-19 mRNA Vaccine À» ¸¸µå´Â °úÁ¤Àº HDT Bio »çÀÇ Chief Scientific Officier ÀÎ Dr. Darrick Carter °¡ ÁøÇàÇÏ´Â ¾Æ·¡ ¼¼¹Ì³ª µ¿¿µ»óÀ» ÂüÁ¶ÇϽʽÿä.

±×¸®°í LION¢â RNA Delivery System °ü·Ã ÀÚ¼¼ÇÑ ³»¿ëÀº ´ÙÀ½ »çÀÌÆ®¸¦ ÂüÁ¶ÇϽʽÿä.
- bioRxiv





¡Ø ÀÌ È­¸éÀ» click ÇϽøé Youtube µ¿¿µ»óÀ¸·Î À̵¿µË´Ï´Ù.

ÀÌ ¹ßÇ¥´Â ´ÙÀ½°ú °°Àº ³»¿ëÀ¸·Î ÀÌ·ç¾î Á® ÀÖ½À´Ï´Ù.

- Overview of RNA from discovery to approval of an mRNA vaccine in 2020
- LNPs, CNEs and LION¢â - The limitations and advantages of major delivery systems
  in use for RNA
- How self-amplifying RNAs work
- Vaccine results with LION¢â, a next generation RNA delivery system
- Future uses of mRNA Technology for medical breakthroughs
- Cost consideration for scale-up
- Using Microfluidizer¢ç processors in manufacturing for global commercial distribution











 
(ÁÖ)¿µÁøÄÚÆÛ·¹ÀÌ¼Ç   |   ´ëÇ¥ : ÀÌÇü¿­   |   »ç¾÷ÀÚµî·Ï¹øÈ£ : 138-81-34745
±º Æ÷ º» »ç   |   (15853) °æ±âµµ ±ºÆ÷½Ã ÇѼ¼·Î 48 ³²¿øºôµù 2Ãþ   |   ÀüÈ­ : 1577-7956 (1)   |   Æѽº : 031-457-9188   |   À̸ÞÀÏ : info@yjcorp.co.kr
´ë Àü Áö »ç   |   (34036) ´ëÀü½Ã À¯¼º±¸ Å×Å©³ë10·Î 29 ÆÄÅ©ÆÓ¸®½º 2Ãþ   |   ÀüÈ­ : 1577-7956 (2)   |   Æѽº : 042-932-1266   |   À̸ÞÀÏ : info@yjcorp.co.kr